title: Chronic active Epstein-Barr virus infection (CAEBV) successfully treated with allogeneic peripheral blood stem cell transplantation.
abstract: We report a pediatric case of CAEBV and T cell-based Hodgkin's-like disease successfully treated with allo PBSCT from an HLA-matched sibling. The diagnosis of CAEBV was made from clinical signs and the presence of the EBV genome in PBMC and tumor cells. Conditioning with busulfan (BU) + etoposide (VP16) + cyclophosphamide (CY) was effective and well tolerated. EBV was totally eradicated by 3 months after allo PBSCT. Although she suffered from chronic GVHD of the liver, she has been well and free of disease for 47 months since PBSCT. We suggest allo PBSCT for CAEBV as a potent therapeutic strategy for eradication of the EBV genome and allowing immunological reconstitution.
authors.affiliation: Division of Hematology/Oncology, Saitama Children's Medical Center, 2100 Magone Iwatsuki, Saitama 339-8551, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Taketani
authors.forename: A
authors.initials: A
authors.lastname: Kikuchi
authors.forename: J
authors.initials: J
authors.lastname: Inatomi
authors.forename: R
authors.initials: R
authors.lastname: Hanada
authors.forename: H
authors.initials: H
authors.lastname: Kawaguchi
authors.forename: K
authors.initials: K
authors.lastname: Ida
authors.forename: T
authors.initials: T
authors.lastname: Oh-Ishi
authors.forename: T
authors.initials: T
authors.lastname: Arai
authors.forename: H
authors.initials: H
authors.lastname: Kishimoto
authors.forename: K
authors.initials: K
authors.lastname: Yamamoto
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002066:Busulfan / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D002908:Chronic Disease; D003131:Combined Modality Therapy / Q000379:methods; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000175:diagnosis / Q000601:surgery*; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D004854:Herpesvirus 4, Human / Q000235:genetics / Q000302:isolation & purification; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D017403:In Situ Hybridization / Q000379:methods; D008223:Lymphoma / Q000150:complications / Q000175:diagnosis / Q000601:surgery / Q000821:virology; D033581:Stem Cell Transplantation; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous / Q000009:adverse effects
chemical_list: D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D005047:Etoposide; D003520:Cyclophosphamide; D002066:Busulfan